Literature DB >> 17006609

Pancreatoduodenectomy for distal cholangiocarcinoma: prognostic impact of lymph node metastasis.

Yoshiaki Murakami1, Kenichiro Uemura, Yasuo Hayashidani, Takeshi Sudo, Hiroki Ohge, Taijiro Sueda.   

Abstract

BACKGROUND: The aim of this study was to identify useful prognostic factors in patients undergoing pancreatoduodenectomy for distal cholangiocarcinoma.
METHODS: The records of 36 patients with distal cholangiocarcinoma undergoing pancreatoduodenectomy were retrospectively reviewed. Potential clinicopathological prognostic factors that may affect survival were examined by univariate and multivariate analysis.
RESULTS: There was no mortality. Overall survival rates were 75%, 54%, and 50% for 1, 3 and 5 years, respectively (median survival time, 26 months). Univariate analysis found that age (>== 65 years), pancreatic invasion, duodenal invasion, lymph node metastasis, perineural invasion and a positive surgical margin were significant predictors of poor prognosis (P < 0.05). Furthermore, lymph node metastasis was found to be a significant independent predictor of poor prognosis by multivariate analysis (P = 0.043). Moreover, there were significant differences in the 5-year survival between patients with 2 or less involved lymph nodes and those with 3 or more positive nodes (P < 0.001). There were no 2-year survivors of the group of patients with 3 or more positive nodes.
CONCLUSIONS: These results suggest that the presence and number of lymph nodes exhibiting metastatic disease might be useful in predicting the postsurgical outcome in patients undergoing pancreatoduodenectomy for distal cholangiocarcinoma.

Entities:  

Mesh:

Year:  2007        PMID: 17006609     DOI: 10.1007/s00268-006-0224-0

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  25 in total

1.  Outcome of treatment for distal bile duct cancer.

Authors:  Y Fong; L H Blumgart; E Lin; J G Fortner; M F Brennan
Journal:  Br J Surg       Date:  1996-12       Impact factor: 6.939

2.  Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer.

Authors:  M Penz; G V Kornek; M Raderer; H Ulrich-Pur; W Fiebiger; A Lenauer; D Depisch; G Krauss; B Schneeweiss; W Scheithauer
Journal:  Ann Oncol       Date:  2001-02       Impact factor: 32.976

3.  Surgical treatment and postoperative outcomes for middle and lower bile duct carcinoma in Japan--experience of a single institute.

Authors:  M Suzuki; M Unno; M Oikawa; K Endo; Y Katayose; S Matsuno
Journal:  Hepatogastroenterology       Date:  2000 May-Jun

4.  Patterns and relevant factors of tumor recurrence for extrahepatic bile duct carcinoma after radical resection.

Authors:  Seung-Woo Park; Young Soo Park; Jae Bock Chung; Jin Kyung Kang; Kyung Sik Kim; Jin Sup Choi; Woo-Jung Lee; Byong Ro Kim; Si Young Song
Journal:  Hepatogastroenterology       Date:  2004 Nov-Dec

5.  Prognostic factors after pancreatoduodenectomy with extended lymphadenectomy for distal bile duct cancer.

Authors:  Takanori Yoshida; Toshifumi Matsumoto; Atsushi Sasaki; Yuji Morii; Masanori Aramaki; Seigo Kitano
Journal:  Arch Surg       Date:  2002-01

6.  Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.

Authors:  Steven R Alberts; Hani Al-Khatib; Michelle R Mahoney; Lawerence Burgart; Peter J Cera; Patrick J Flynn; Tom R Finch; Ralph Levitt; Harold E Windschitl; James A Knost; Loren K Tschetter
Journal:  Cancer       Date:  2005-01-01       Impact factor: 6.860

7.  Surgical management of 552 carcinomas of the extrahepatic bile ducts (gallbladder and periampullary tumors excluded). Results of the French Surgical Association Survey.

Authors:  R Reding; J L Buard; G Lebeau; B Launois
Journal:  Ann Surg       Date:  1991-03       Impact factor: 12.969

8.  Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors.

Authors:  A Nakeeb; H A Pitt; T A Sohn; J Coleman; R A Abrams; S Piantadosi; R H Hruban; K D Lillemoe; C J Yeo; J L Cameron
Journal:  Ann Surg       Date:  1996-10       Impact factor: 12.969

9.  Changing trends in the management of extrahepatic cholangiocarcinoma.

Authors:  C M Guthrie; G Haddock; A C De Beaux; O J Garden; D C Carter
Journal:  Br J Surg       Date:  1993-11       Impact factor: 6.939

10.  Carcinoma of the extrahepatic bile ducts. The University of California at San Francisco experience.

Authors:  R Schoenthaler; T L Phillips; J Castro; J T Efird; A Better; L W Way
Journal:  Ann Surg       Date:  1994-03       Impact factor: 12.969

View more
  29 in total

Review 1.  Laparoscopic Completion Pancreatectomy for Local Recurrence in the Pancreatic Remnant after Pancreaticoduodenectomy: Case Reports and Review of the Literature.

Authors:  Mushegh A Sahakyan; Sheraz Yaqub; Airazat M Kazaryan; Olaug Villanger; Audun Elnæs Berstad; Knut Jørgen Labori; Bjørn Edwin; Bård Ingvald Røsok
Journal:  J Gastrointest Cancer       Date:  2016-12

Review 2.  Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009.

Authors:  Murad Aljiffry; Mark J Walsh; Michele Molinari
Journal:  World J Gastroenterol       Date:  2009-09-14       Impact factor: 5.742

3.  Pancreaticoduodenectomy for distal cholangiocarcinoma: surgical results, prognostic factors, and long-term follow-up.

Authors:  Stefano Andrianello; Salvatore Paiella; Valentina Allegrini; Marco Ramera; Alessandra Pulvirenti; Giuseppe Malleo; Roberto Salvia; Claudio Bassi
Journal:  Langenbecks Arch Surg       Date:  2015-07-02       Impact factor: 3.445

4.  Preliminary experience with CT-guided high-dose rate brachytherapy as an alternative treatment for hepatic recurrence of cholangiocarcinoma.

Authors:  Carsten Kamphues; Daniel Seehofer; Federico Collettini; Marcus Bahra; Peter Neuhaus; Peter Wust; Timm Denecke; Bernhard Gebauer; Dirk Schnapauff
Journal:  HPB (Oxford)       Date:  2012-08-28       Impact factor: 3.647

5.  Intrapancreatic distal common bile duct carcinoma: Analysis, staging considerations, and comparison with pancreatic ductal and ampullary adenocarcinomas.

Authors:  Raul S Gonzalez; Pelin Bagci; Olca Basturk; Michelle D Reid; Serdar Balci; Jessica H Knight; So Yeon Kong; Bahar Memis; Kee-Taek Jang; Nobuyuki Ohike; Takuma Tajiri; Sudeshna Bandyopadhyay; Alyssa M Krasinskas; Grace E Kim; Jeanette D Cheng; N Volkan Adsay
Journal:  Mod Pathol       Date:  2016-07-29       Impact factor: 7.842

Review 6.  The survival outcome and prognostic factors for distal cholangiocarcinoma following surgical resection: a meta-analysis for the 5-year survival.

Authors:  U F Wellner; YinFeng Shen; T Keck; WenYin Jin; Ze Xu
Journal:  Surg Today       Date:  2016-05-28       Impact factor: 2.549

7.  A case of distal extrahepatic cholangiocarcinoma with two positive resection margins.

Authors:  Wayne A Warner; Wesley Ramcharan; Dave Harnanan; Srikanth Umakanthan; Ravi Maharaj
Journal:  Oncol Lett       Date:  2016-09-22       Impact factor: 2.967

8.  Over 700 Whipples for Pancreaticobiliary Malignancies: Postoperative Morbidity Is an Additional Negative Prognostic Factor for Distal Bile Duct Cancer.

Authors:  Stefano Andrianello; Giovanni Marchegiani; Giuseppe Malleo; Borislav Chavdarov Rusev; Aldo Scarpa; Deborah Bonamini; Laura Maggino; Claudio Bassi; Roberto Salvia
Journal:  J Gastrointest Surg       Date:  2016-11-23       Impact factor: 3.452

9.  Surgical strategy for bile duct cancer: Advances and current limitations.

Authors:  Nobuhisa Akamatsu; Yasuhiko Sugawara; Daijo Hashimoto
Journal:  World J Clin Oncol       Date:  2011-02-10

10.  Prognostic significance of contrast-enhanced CT attenuation value in extrahepatic cholangiocarcinoma.

Authors:  Yoshiki Asayama; Akihiro Nishie; Kousei Ishigami; Yasuhiro Ushijima; Yukihisa Takayama; Daisuke Okamoto; Nobuhiro Fujita; Takao Ohtsuka; Tomoharu Yoshizumi; Shinichi Aishima; Yoshinao Oda; Hiroshi Honda
Journal:  Eur Radiol       Date:  2016-10-17       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.